Phase 1 Test-retest Evaluation of [18F]MNI-958 PET



Status:Recruiting
Conditions:Alzheimer Disease, Healthy Studies, Neurology
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 55
Updated:3/23/2019
Start Date:March 12, 2018
End Date:March 12, 2020
Contact:Rhea Martin
Email:rmartin@invicro.com
Phone:2034014300

Use our guide to learn which trials are right for you!

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers

The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or
PM-PBB3, a tau targeted radiopharmaceutical.

The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or
PM-PBB3, a tau targeted radiopharmaceutical. The specific objectives are:

- To measure the dynamic uptake and washout of [18F]MNI- 958 in brain using positron
emission tomography (PET) in patients with Alzheimer's disease, Progressive Supranuclear
Palsy and healthy volunteers.

- To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its
ability to measure tau protein in brain using the tracer plasma concentration or a
reference region as indirect input.

- To obtain test/retest reliability of the tracer binding parameters in patients with
Alzheimer's disease, Progressive Supranuclear Palsy and healthy volunteers.

- To acquire safety data following injection of [18F]MNI-958.

Inclusion Criteria (for all subjects):

- Written informed consent must be obtained before any assessment is performed.

- Female subjects must be documented by medical records or physician's note to be either
surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal
ligation) or post-menopausal for at least 1 year or, if they are of childbearing
potential, must commit to use a barrier contraception method for the duration of the
study.

- Male subjects and their partners of childbearing potential must commit to the use of
two methods of contraception, one of which is a barrier method for male subjects for
the study duration.

- Male subjects must not donate sperm for the study duration.

- Willing and able to cooperate with study procedures

Inclusion criteria for healthy volunteer subjects

- Males and females aged ≥50 years. Healthy with no clinically relevant finding on
physical examination at screening and upon reporting for the [18F]MNI-958 imaging
visit.

- No cognitive impairment from neuropsychological battery as judged by the investigator

- Have screening or prior (in the last 90 days) amyloid PET imaging demonstrating no
significant amyloid binding based on qualitative (visual read).

- No family history of Alzheimer's disease or neurological disease associated with
dementia

- Have a CDR global score=0

- Have an MMSE score ≥28

- Willing and able to cooperate with study procedures

Inclusion criteria for subjects with a diagnosis of probable

Alzheimer's disease (AD):

- Males and females aged 50 to 80 years.

- Have probable Alzheimer's disease dementia, based on the NINCDS/ADRDA and DSM-IV
criteria, with mild severity and amnestic presentation

- Have a CDR score ≥ 0.5 at screening

- Have a MMSE score between ≤ 28.

- Have screening or prior (in the last 12 months) amyloid PET imaging demonstrating
amyloid binding based on qualitative analysis (visual read). Amyloid PET imaging
results will be shared with participants, and scans may be used by participants for
future research use.

- A brain MRI that supports a diagnosis of AD, with no evidence of significant
neurologic pathology.

- Medications taken for symptomatic treatment of AD must be maintained on a stable
dosage regimen for at least 30 days before screening visit.

- The subject has an appropriate caregiver capable of accompanying subject on all
visits.

- Signed and dated written informed consent obtained from the subject and the subject's
legally authorized representative or caregiver (if applicable).

Inclusion criteria for subjects with a diagnosis of Progressive Supranuclear Palsy (PSP)

- Males and females aged 50 to 90 years.

- Has a clinical diagnosis of probable PSP based on the NINDS and Society for PSP
(NINDS-PSP) criteria (Litvan, et al 1996).

- Have screening or prior DaTscan SPECT imaging demonstrating evidence of dopamine
transporter deficit based on visual read.

- A brain MRI that supports a diagnosis of PSP, with no other evidence of significant
neurologic pathology

- Medications taken for symptomatic treatment of PSP must be maintained on a stable
dosage regimen for at least 30 days before screening visit.

- The subject has an appropriate caregiver capable of accompanying subject, if
necessary.

- Signed and dated written informed consent obtained from the subject and the subject's
legally authorized representative or caregiver (if applicable).

Exclusion Criteria:

- Exclusion Criteria (for All subjects)

- Current or prior history (in the last 12 months) of any alcohol or drug abuse.

- Laboratory tests with clinically significant abnormalities and/or clinically
significant unstable medical illness.

- Subject has received an investigational drug or device within 30 days of
screening

- Prior participation in other research protocols or clinical care in the last year
in addition to the radiation exposure expected from participation in this
clinical study, such that radiation exposure exceeds the effective dose of 50
mSv, which would be above the acceptable annual limit established by the US
Federal Guidelines.

- Pregnancy, lactating or breastfeeding.

- Evidence of clinically significant gastrointestinal, cardiovascular, hepatic,
renal, hematological, neoplastic, endocrine, alternative neurological,
immunodeficiency, pulmonary, or other disorder or disease.

- Unsuitable veins for repeated venipuncture.

- MRI exclusion criteria include: Findings that may be responsible for the
neurologic status of the patient such as significant evidence of cerebrovascular
disease (more than two lacunar infarcts, any territorial infarct >1cm3, or deep
white matter abnormality corresponding to an overall Fazekas scale of 3 with at
least one confluent hyperintense lesion on the FLAIR sequence that is ≥20 mm in
any dimension), infectious disease, space-occupying lesions, normal pressure
hydrocephalus or any other abnormalities associated with CNS disease.

- Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps,
cochlear implants, metallic ocular foreign body, implanted neural stimulators,
CNS aneurysm clips and other medical implants that have not been certified for
MRI, or history of claustrophobia in MRI.

Exclusion criteria for subjects with AD:

• Has received treatment that targeted Aβ or tau within the last 3 months.

Exclusion criteria for subjects PSP:

- Ongoing treatment with methylphenidate, modafinil, metoclopramide, alpha methyldopa,
reserpine, or amphetamine derivative for subjects requiring DaTscan imaging.

- Subjects may take stable doses of bupropion, however this medication must be held for
at least 12 hours prior to DaTscan imaging.
We found this trial at
1
site
60 Temple Street
New Haven, Connecticut 06510
Principal Investigator: David Russell, MD, PhD
Phone: 203-401-4300
?
mi
from
New Haven, CT
Click here to add this to my saved trials